Nkarta, Inc. financial data

Symbol
NKTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1150 Veterans Boulevard, South San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.42K % +4.13%
Debt-to-equity 28 % -6.08%
Return On Equity -28.8 % +17.2%
Return On Assets -22.5 % +16%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 70.6M shares +43.8%
Common Stock, Shares, Outstanding 49.2M shares +0.62%
Entity Public Float 38.4M USD -88.9%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 73.5M shares +50.1%
Weighted Average Number of Shares Outstanding, Diluted 73.5M shares +50.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 93.9M USD -7.54%
General and Administrative Expense 30.1M USD -13.8%
Operating Income (Loss) -124M USD +9.13%
Nonoperating Income (Expense) 16M USD +40.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -108M USD +13.7%
Earnings Per Share, Basic -2.01 USD/shares +20.2%
Earnings Per Share, Diluted -2.01 USD/shares +20.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 120M USD +313%
Other Assets, Current 1.62M USD -44.7%
Assets, Current 332M USD +15.7%
Property, Plant and Equipment, Net 77.6M USD +1.92%
Operating Lease, Right-of-Use Asset 39.4M USD -4.13%
Other Assets, Noncurrent 3.53M USD -3.63%
Assets 554M USD +29.1%
Accounts Payable, Current 3.76M USD +25.1%
Employee-related Liabilities, Current 4.92M USD -0.24%
Accrued Liabilities, Current 11.6M USD -34.1%
Liabilities, Current 20.9M USD -21.6%
Operating Lease, Liability, Noncurrent 80M USD -5.22%
Other Liabilities, Noncurrent 5K USD -91.1%
Liabilities 101M USD -9.15%
Accumulated Other Comprehensive Income (Loss), Net of Tax -263K USD +56.2%
Retained Earnings (Accumulated Deficit) -490M USD -28.2%
Stockholders' Equity Attributable to Parent 453M USD +42.5%
Liabilities and Equity 554M USD +29.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.5M USD -37.3%
Net Cash Provided by (Used in) Financing Activities 226M USD +22527%
Net Cash Provided by (Used in) Investing Activities 21.5M USD -41.8%
Common Stock, Shares Authorized 200M shares
Common Stock, Shares, Issued 49.2M shares +0.62%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 219M USD +1256%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 123M USD +287%
Deferred Tax Assets, Valuation Allowance 102M USD +43.2%
Deferred Tax Assets, Gross 118M USD +31%
Operating Lease, Liability 85.6M USD -5.44%
Payments to Acquire Property, Plant, and Equipment 175K USD -96.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -108M USD +13.7%
Lessee, Operating Lease, Liability, to be Paid 135M USD -8.41%
Property, Plant and Equipment, Gross 93.8M USD +12.2%
Operating Lease, Liability, Current 5.53M USD -8.56%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.5M USD +3.34%
Lessee, Operating Lease, Liability, to be Paid, Year One 13.4M USD +5.37%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 49M USD -13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13.9M USD +3.34%
Deferred Tax Assets, Operating Loss Carryforwards 43.5M USD +18.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 54.4M shares 0%
Unrecognized Tax Benefits 3.74M USD +59.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 14.4M USD +3.35%
Operating Lease, Payments 3.3M USD -43.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 8.9M USD +197%
Deferred Tax Assets, Net of Valuation Allowance 16.3M USD -14.7%
Share-based Payment Arrangement, Expense 16.6M USD -9.09%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%